Lactiplantibacillus plantarum 299v (LP299V®) (DSM 9843)


Lactiplantibacillus plantarum 299v (LP299V®) is the most clinically documented L. plantarum strain in the world. LP299V® has been documented within several areas, all related to health benefits in the gut. It is described in more than 200 scientific publications and has been subject to more than 70 clinical studies. Clinical results have been shown within areas reaching from inflammation to metabolic health. The extensive documentation and clinical evidence make this strain unique and ideal for building consumer loyalty.

Probi Digestis® is based on the LP299V® strain, understand the probiotic mode of action in this video:

LP299V® is a registered trademark of Probi AB.

The strain is patent-protected and approved for a wide range of indications and applications worldwide.

Scientific reference(s)

More than 70 clinical studies in total.

Irritable Bowel Syndrome (IBS)
Ducrotte, P., P. Sawant, and V. Jayanthi, Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol, 2012. 18(30): p. 4012-8.

Niedzielin, K., H. Kordecki, and B. Birkenfeld, A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299v in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol, 2001. 13(10): p. 1143-7.

Krammer, H., et al., [Treatment of IBS with Lactobacillus plantarum 299v: Therapeutic success increases with length of treatment - real-life data of a non-interventional study in Germany]. Z Gastroenterol, 2021. 59(2): p. 125-134.

Clostridioides Difficile Infection (CDI)
Kujawa-Szewieczek, A., et al., The Effect of Lactobacillus plantarum 299v on the Incidence of Clostridium difficile Infection in High Risk Patients Treated with Antibiotics. Nutrients, 2015. 7(12): p. 10179-88.

Dudzicz, S., et al., Lactobacillus plantarum 299v Reduces the Incidence of Clostridium difficile Infection in Nephrology and Transplantation Ward-Results of One Year Extended Study. Nutrients, 2018. 10(11).

Antibiotic Associated Diarrhea (AAD)
Lonnermark, E., et al., Intake of Lactobacillus plantarum reduces certain gastrointestinal symptoms during treatment with antibiotics. J Clin Gastroenterol, 2010. 44(2): p. 106-12.

Mack, D.R., et al., Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol, 1999. 276(4): p. G941-50.

Mack, D.R., et al., Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut, 2003. 52(6): p. 827-33.

Adlerberth, I., et al., A mannose-specific adherence mechanism in Lactobacillus plantarum conferring binding to the human colonic cell line HT-29. Appl Environ Microbiol, 1996. 62(7): p. 2244-51.

Additional info

Therapeutical area(s)

Cardiometabolic · Gastrointestinal tract · Gut brain Axis · Women health




Adults · Children · Elderly · Women

Lactiplantibacillus plantarum 299v (LP299V®) (DSM 9843) is available at

Probiotic blends with Lactiplantibacillus plantarum 299v (LP299V®) (DSM 9843)

Scroll to Top
Browse companies by type
Brought to you by